Pan-immune-inflammation value for risk stratification of adverse cardiovascular outcomes in acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review and meta-analysis - Summary - MDSpire
Advertisement
Pan-immune-inflammation value for risk stratification of adverse cardiovascular outcomes in acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review and meta-analysis
To evaluate the prognostic and discriminatory value of pan-immune-inflammation value (PIV) in adults with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).
Key Findings:
Higher PIV was associated with MACE (adjusted HR 1.65, 95% CI 1.20–2.27; low certainty).
Higher PIV was associated with all-cause mortality (HR 3.51, 95% CI 2.15–5.74; moderate certainty).
PIV showed consistent discrimination for no-reflow or slow-flow (AUC 0.828, 95% CI 0.808–0.846; moderate certainty).
Heterogeneous discrimination for post-contrast renal injury (AUC 0.771, 95% CI 0.617–0.875; very low certainty).
Interpretation:
Limitations:
Evidence is limited by observational designs.
Small numbers of studies for several outcomes.
Heterogeneous cut-offs for PIV.
Moderate to high risk of bias in included studies.
These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.
